5-formyl-N-methylfuran-2-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-formyl-N-methylfuran-2-carboxamide
• 化学式: C₇H₇NO₃
• 分子量: 153.137
• InChiKey: BKBDBTAYELYFJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Boc-d-2-茚烷甘氨酸 、 5-formyl-N-methylfuran-2-carboxamide 、 异氰化异丙酯 、 (R)-leucine methyl ester hydrochloride 在 三乙胺 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  The discovery of GSK221149A: A potent and selective oxytocin antagonist

  摘要：

  Optimisation of a series of oxazole diketopiperazines has led to the discovery of a very potent and selective oxytocin antagonist GSK221149A. GSK221149A has been shown to inhibit oxytocin-induced uterine contractions in the anaesthetised rat. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.008
• 作为产物：
  描述：

  5-甲醛基呋喃-2-羧酸 、 甲胺 在 草酰氯 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 以40%的产率得到5-formyl-N-methylfuran-2-carboxamide
  参考文献：
  名称：

  Isolation of a Melanoblast Stimulator from Dimocarpus longan, Its Structural Modification, and Structure–Activity Relationships for Vitiligo

  摘要：

  一种新的黑素细胞刺激剂（1）从龙眼中分离出来。它的类似物也被合成，以支持一种基于呋喃的黑素细胞刺激剂骨架，用于治疗白癜风。分离出的5-（羟甲基）糠醛（HMF，1）是食品工业中众所周知的化合物。令人惊讶的是，这里首次发现了HMF（1）的黑色素活性。无论是HMF还是其合成的类似物（16），都可以促进黑素细胞在体外的分化和迁移。通常，刺激剂（1）上调MMP2的表达，促进黑素细胞在体外的迁移。

  DOI：

  10.3390/molecules27072135

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CALIFORNIA

  公开号：WO2018005678A1

  公开（公告）日：2018-01-04

  The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.

  本公开提供了化合物、药物组合物以及治疗癌症和纤维化的方法。所述的药物组合物可能包括一个或多个吡唑基含有化合物，或其衍生物。
• TRICYCLIC PIPERIDINE COMPOUNDS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160272655A1

  公开（公告）日：2016-09-22

  The present invention relates to compounds of the formula (I) wherein R, R 1a , R 1b , R 2 , R 3 , and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

  本发明涉及式（I）的化合物，其中R、R1a、R1b、R2、R3和X如描述中所述，其制备方法，其药学上可接受的盐以及它们作为药物的用途，含有一个或多个式（I）化合物的药物组合物，制备这种式（I）化合物的方法，特别是它们作为TPH调节剂的用途。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
  申请人：The Regents of the University of California

  公开号：EP3478284A1

  公开（公告）日：2019-05-08
• Compounds and Compositions for the Treatment of Cancer
  申请人：The Regents of the University of California

  公开号：US20210009523A1

  公开（公告）日：2021-01-14

  The present disclosure provides compounds, pharmaceutical compositions, and methods for the treatment of cancer and fibrosis. The disclosed pharmaceutical compositions may include one or more pyrazolyl-containing compounds, or a derivative thereof.
• Pharmaceutical Composition for Preventing Greying of Hair and Preventing or Treating Poliosis or Vitiligo
  申请人：INHA University Research and Business Foundation

  公开号：US20220000832A1

  公开（公告）日：2022-01-06

  The present invention relates to a pharmaceutical composition for preventing greying of hair, and preventing or treating poliosis or vitiligo. The pharmaceutical composition of the present invention increases intracellular melanin content, accelerates or increases melanoblast migration, pre-emptively prevents gray hair formation, and accelerates dark hair formation, and thus may be beneficially used in the prevention or alleviation of greying of hair, and in the prevention, alleviation or treatment of poliosis or vitiligo.